Oct 08, 2019
CT Psychiatrist Shows Titrated IV Ketamine Can STOP Suicidality
Oct 07, 2019
Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology
Oct 03, 2019
Pacific Ketamine Institute Introduces SPRAVATO(TM) Treatment for Depression and Mental Disorders
Oct 02, 2019
Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
Sep 25, 2019
Katerzia(TM), the First and Only Amlodipine Oral Suspension, 1 mg/mL, is Now Commercially Available for Pediatric Patients 6 Years of Age and Older
Sep 23, 2019
Sandoz Inc. Issues Voluntary Recall of Ranitidine Hydrochloride Capsules 150mg and 300mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA), in the Product
Sep 16, 2019
Dr. David Mahjoubi Announces Move to a New Location for the Ketamine Healing Clinic of Los Angeles
Sep 10, 2019
Updated Phase 1 Data for Daiichi Sankyo's U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer
Aug 28, 2019
IRLAB to Advance Clinical Development of IRL790 in LIDs Based on In-depth Analysis of Positive Phase IIa Results
Aug 21, 2019
Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA(TM)
Aug 20, 2019
Global Aquatic Herbicides Market Analysis, Trends, Drivers and Restraints During the Forecast Period, 2017-2027 - ResearchAndMarkets.com
Aug 20, 2019
The Ketamine Healing Clinic of Los Angeles's Dr. David Mahjoubi is Featured in the Mic.com Article, "How Does Ketamine Treat Depression, and is it Safe?"
Aug 16, 2019
IV Ketamine Infusions Dramatically Improve the Quality of Life for Severe Migraine Patient
Aug 02, 2019
Global Animal Feed Additives Market Analysis by Product, Livestock and Region (2014-2025) - ResearchAndMarkets.com
Jul 29, 2019
Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
Jul 23, 2019
Kalypso Wellness Center Patients See 90 Success Rates
Jul 11, 2019
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA(TM) for Pruritus in Patients with Atopic Dermatitis
Jul 10, 2019
FDA Approves Katerzia(TM), the First and Only Amlodipine Oral Suspension, 1 mg/mL, for Pediatric Patients 6 Years of Age and Older
Jun 27, 2019
Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Second Pruritus Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA(TM)
Jun 21, 2019
Fursultiamine (CAS 804-30-8) Market Research Report 2019 - ResearchAndMarkets.com